Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Unravelling Alzheimer's Disease: It's Not the Whole Story, but Aβ Still Matters.

Buxbaum JN.

FASEB J. 2019 Sep;33(9):9701-9705. doi: 10.1096/fj.201901895.

PMID:
31465249
2.

Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.

Buxbaum JN.

Amyloid. 2019 Jun;26(2):55-65. doi: 10.1080/13506129.2019.1575201. Epub 2019 Mar 24. Review.

PMID:
30907141
3.

Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.

Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M.

Amyloid. 2019 Mar;26(1):10-14. doi: 10.1080/13506129.2018.1554563. Epub 2019 Jan 24.

PMID:
30675806
4.

Identification of transthyretin as a novel interacting partner for the δ subunit of GABAA receptors.

Zhou L, Tang X, Li X, Bai Y, Buxbaum JN, Chen G.

PLoS One. 2019 Jan 7;14(1):e0210094. doi: 10.1371/journal.pone.0210094. eCollection 2019.

5.

Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.

Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P.

Amyloid. 2018 Dec;25(4):215-219. doi: 10.1080/13506129.2018.1549825. Epub 2019 Jan 7.

PMID:
30614283
6.

Oligonucleotide Drugs for Transthyretin Amyloidosis.

Buxbaum JN.

N Engl J Med. 2018 Nov 22;379(21):2086. doi: 10.1056/NEJMc1810994. No abstract available.

PMID:
30462941
7.

Oligonucleotide Drugs for Transthyretin Amyloidosis.

Buxbaum JN.

N Engl J Med. 2018 Jul 5;379(1):82-85. doi: 10.1056/NEJMe1805499. No abstract available.

PMID:
29972750
8.

Summary: FASEB Science Research Conference on Protein Aggregation in Health and Disease.

Buxbaum JN, Morgan GJ.

FASEB J. 2018 Mar;32(3):1125-1129. doi: 10.1096/fj.201701266. No abstract available.

9.

Inhibition of amyloid beta fibril formation by monomeric human transthyretin.

Garai K, Posey AE, Li X, Buxbaum JN, Pappu RV.

Protein Sci. 2018 Jul;27(7):1252-1261. doi: 10.1002/pro.3396. Epub 2018 Mar 14.

10.

Inhibition of curli assembly and Escherichia coli biofilm formation by the human systemic amyloid precursor transthyretin.

Jain N, Ådén J, Nagamatsu K, Evans ML, Li X, McMichael B, Ivanova MI, Almqvist F, Buxbaum JN, Chapman MR.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12184-12189. doi: 10.1073/pnas.1708805114. Epub 2017 Oct 30.

11.

Transthyretin deposition promotes progression of osteoarthritis.

Matsuzaki T, Akasaki Y, Olmer M, Alvarez-Garcia O, Reixach N, Buxbaum JN, Lotz MK.

Aging Cell. 2017 Dec;16(6):1313-1322. doi: 10.1111/acel.12665. Epub 2017 Sep 22.

12.

Transthyretin and BRICHOS: The Paradox of Amyloidogenic Proteins with Anti-Amyloidogenic Activity for Aβ in the Central Nervous System.

Buxbaum JN, Johansson J.

Front Neurosci. 2017 Mar 15;11:119. doi: 10.3389/fnins.2017.00119. eCollection 2017. Review.

14.

Alzheimer's Disease: It's More Than Aβ.

Buxbaum JN.

FASEB J. 2017 Jan;31(1):2-4. doi: 10.1096/fj.201601179. Review. No abstract available.

PMID:
28049154
15.

Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.

Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, Westermark P.

Amyloid. 2016 Dec;23(4):209-213. Epub 2016 Nov 24.

PMID:
27884064
16.

The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa.

Jacobson DR, Alexander AA, Tagoe C, Garvey WT, Williams SM, Tishkoff S, Modiano D, Sirima SB, Kalidi I, Toure A, Buxbaum JN.

Mol Genet Genomic Med. 2016 Jul 14;4(5):548-56. doi: 10.1002/mgg3.231. eCollection 2016 Sep.

17.

Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.

Kurian SM, Novais M, Whisenant T, Gelbart T, Buxbaum JN, Kelly JW, Coelho T, Salomon DR.

Theranostics. 2016 Jul 18;6(11):1792-809. doi: 10.7150/thno.14584. eCollection 2016.

18.

Transthyretin Suppresses Amyloid-β Secretion by Interfering with Processing of the Amyloid-β Protein Precursor.

Li X, Song Y, Sanders CR, Buxbaum JN.

J Alzheimers Dis. 2016 Apr 8;52(4):1263-75. doi: 10.3233/JAD-160033.

19.

Effect of molecular chaperones on aberrant protein oligomers in vitro: super-versus sub-stoichiometric chaperone concentrations.

Cappelli S, Penco A, Mannini B, Cascella R, Wilson MR, Ecroyd H, Li X, Buxbaum JN, Dobson CM, Cecchi C, Relini A, Chiti F.

Biol Chem. 2016 May;397(5):401-15. doi: 10.1515/hsz-2015-0250.

PMID:
26812789
20.

Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.

Damy T, Costes B, Hagège AA, Donal E, Eicher JC, Slama M, Guellich A, Rappeneau S, Gueffet JP, Logeart D, Planté-Bordeneuve V, Bouvaist H, Huttin O, Mulak G, Dubois-Randé JL, Goossens M, Canoui-Poitrine F, Buxbaum JN.

Eur Heart J. 2016 Jun 14;37(23):1826-34. doi: 10.1093/eurheartj/ehv583. Epub 2015 Nov 3.

PMID:
26537620
21.

Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans.

Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN.

Amyloid. 2015;22(3):171-4. doi: 10.3109/13506129.2015.1051219. Epub 2015 Jul 2.

PMID:
26123279
22.

Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis.

Akasaki Y, Reixach N, Matsuzaki T, Alvarez-Garcia O, Olmer M, Iwamoto Y, Buxbaum JN, Lotz MK.

Arthritis Rheumatol. 2015 May;67(8):2097-107. doi: 10.1002/art.39178.

23.

The amyloidogenic V122I transthyretin variant in elderly black Americans.

Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD.

N Engl J Med. 2015 Jan 1;372(1):21-9. doi: 10.1056/NEJMoa1404852.

24.

Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis.

Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P.

Amyloid. 2014 Dec;21(4):221-4. doi: 10.3109/13506129.2014.964858. Epub 2014 Sep 29. No abstract available.

25.

Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuropathologic effects.

Buxbaum JN, Roberts AJ, Adame A, Masliah E.

Neuroscience. 2014 Sep 5;275:352-64. doi: 10.1016/j.neuroscience.2014.06.019. Epub 2014 Jun 21.

PMID:
24956283
26.

The systemic amyloid precursor transthyretin (TTR) behaves as a neuronal stress protein regulated by HSF1 in SH-SY5Y human neuroblastoma cells and APP23 Alzheimer's disease model mice.

Wang X, Cattaneo F, Ryno L, Hulleman J, Reixach N, Buxbaum JN.

J Neurosci. 2014 May 21;34(21):7253-65. doi: 10.1523/JNEUROSCI.4936-13.2014.

27.

Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro.

Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN.

J Neurosci. 2013 Dec 11;33(50):19423-33. doi: 10.1523/JNEUROSCI.2561-13.2013.

28.

Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro.

Cascella R, Conti S, Mannini B, Li X, Buxbaum JN, Tiribilli B, Chiti F, Cecchi C.

Biochim Biophys Acta. 2013 Dec;1832(12):2302-14. doi: 10.1016/j.bbadis.2013.09.011. Epub 2013 Sep 25.

29.

Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.

Zhao L, Buxbaum JN, Reixach N.

Biochemistry. 2013 Mar 19;52(11):1913-26. doi: 10.1021/bi301313b. Epub 2013 Mar 4.

30.

Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis.

Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P; Nomenclature Committee of the International Society of Amyloidosis.

Amyloid. 2012 Dec;19(4):167-70. doi: 10.3109/13506129.2012.734345. Epub 2012 Nov 1.

PMID:
23113696
31.

Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy.

Buxbaum JN.

Degener Neurol Neuromuscul Dis. 2012 Oct 19;2:165-173. doi: 10.2147/DNND.S24624. eCollection 2012. Review.

32.

Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?

Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR.

FASEB J. 2012 Jun;26(6):2283-93. doi: 10.1096/fj.11-189571. Epub 2012 Feb 23.

33.

A molecular history of the amyloidoses.

Buxbaum JN, Linke RP.

J Mol Biol. 2012 Aug 10;421(2-3):142-59. doi: 10.1016/j.jmb.2012.01.024. Epub 2012 Feb 1. Review.

PMID:
22321796
34.

Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?

Li X, Buxbaum JN.

Mol Neurodegener. 2011 Nov 23;6:79. doi: 10.1186/1750-1326-6-79. Review.

35.

Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?

Li X, Masliah E, Reixach N, Buxbaum JN.

J Neurosci. 2011 Aug 31;31(35):12483-90. doi: 10.1523/JNEUROSCI.2417-11.2011.

36.

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N.

Biochem Biophys Res Commun. 2011 Jul 15;410(4):707-13. doi: 10.1016/j.bbrc.2011.04.133. Epub 2011 May 4. Erratum in: Biochem Biophys Res Commun. 2011 Aug 19;412(1):196.

37.

Is older colder or colder older? The association of age with body temperature in 18,630 individuals.

Waalen J, Buxbaum JN.

J Gerontol A Biol Sci Med Sci. 2011 May;66(5):487-92. doi: 10.1093/gerona/glr001. Epub 2011 Feb 15.

38.

Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis.

Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P.

Amyloid. 2010 Sep;17(3-4):101-4. doi: 10.3109/13506129.2010.526812. Epub 2010 Nov 2.

PMID:
21039326
39.

Transthyretin: the servant of many masters.

Buxbaum JN, Reixach N.

Cell Mol Life Sci. 2009 Oct;66(19):3095-101. doi: 10.1007/s00018-009-0109-0. Epub 2009 Jul 31. Review.

40.

Animal models of human amyloidoses: are transgenic mice worth the time and trouble?

Buxbaum JN.

FEBS Lett. 2009 Aug 20;583(16):2663-73. doi: 10.1016/j.febslet.2009.07.031. Epub 2009 Jul 20. Review.

41.

Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity.

Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2681-6. doi: 10.1073/pnas.0712197105. Epub 2008 Feb 12.

42.

An adaptable standard for protein export from the endoplasmic reticulum.

Wiseman RL, Powers ET, Buxbaum JN, Kelly JW, Balch WE.

Cell. 2007 Nov 16;131(4):809-21.

43.

Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteins.

Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum JN.

J Biol Chem. 2008 Jan 25;283(4):2098-107. Epub 2007 Nov 15.

44.

In vivo stabilization of mutant human transthyretin in transgenic mice.

Tagoe CE, Reixach N, Friske L, Mustra D, French D, Gallo G, Buxbaum JN.

Amyloid. 2007 Sep;14(3):227-36.

PMID:
17701470
45.

A primer of amyloid nomenclature.

Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD.

Amyloid. 2007 Sep;14(3):179-83.

PMID:
17701465
46.

Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis?

Bartfai T, Waalen J, Buxbaum JN.

J Rheumatol. 2007 Mar;34(3):488-92. Epub 2007 Feb 15. Review.

PMID:
17309131
47.

Oxidation inhibits amyloid fibril formation of transthyretin.

Maleknia SD, Reixach N, Buxbaum JN.

FEBS J. 2006 Dec;273(23):5400-6.

49.

Cell based screening of inhibitors of transthyretin aggregation.

Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN.

Biochem Biophys Res Commun. 2006 Sep 29;348(3):889-97. Epub 2006 Jul 31.

PMID:
16904635
50.

Supplemental Content

Loading ...
Support Center